Emergent BioSolutions (EBS) Misses Q4 EPS by 81c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.34 +1.77%
EPS Growth %: -138.7%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
JBLU, SICP, OMID, More
EPS Growth %: -138.7%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
JBLU, SICP, OMID, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.43), $0.81 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $148.7 million versus the consensus estimate of $237 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- TPG RE Finance Trust Inc. (TRTX) Misses Q3 EPS by 19c
- Nucor (NUE) Reports In-Line Q3 EPS; offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
